IP Australia to increase fees for patent filings from 1 August 2010

The Commonwealth Government has recently amended the Patents Regulations to increase the fees IP Australia charges for its services in relation to patent filings and related proceedings.

Some of the key increases, which take effect from 1 August 2010, include:

  • filing a request for a standard patent accompanied by a complete specification electronically increases from $290 to $320
  • filing a request for a standard patent accompanied by a complete specification by another means increases from $320 to $370
  • filing a request for examination of a standard patent application increases from $420 to $450
  • filing a request for examination of an innovation patent application increases from $370 to $400
  • filing a notice of opposition increases from $550 to $600
  • filing an application for an extension of the term of a pharmaceutical patent increases from $1,300 to $2,000
  • certain renewal fees and continuation fees

See the amending legislation for a complete list of the new fees and changes.  More information from IP Australia can also be found here.

The amending legislation also introduces some minor administrative changes to the PCT Rules in Schedule 2A of the Patents Regulations, and to enable search results associated with PCT applications to be made open to public inspection.  These changes commenced on 1 July 2010.

About the Author

James Ellsmore
James is a senior associate with King & Wood Mallesons' Intellectual Property team in Sydney. James assists clients to resolve intellectual property disputes, with a particular focus on patents, pharmaceuticals and the life sciences. He has acted for a variety of clients in matters concerning patent infringement and revocation proceedings in the Federal Court of Australia, patent opposition proceedings before the Commissioner of Patents, and matters arising from patent licence and technology agreements. James also has experience in the preparation of commercial, R&D and IP agreements for leading universities, research organisations and pharmaceutical companies. He also advises clients on regulatory issues affecting clients in the industrials, consumer and health sectors.
View all posts by James Ellsmore

Leave a Reply

Your email address will not be published. Required fields are marked *

two × five =